Given the potential difference in therapeutic window with MEK inhibitor and the importance of NF1 levels for successful RA therapy (Holzel et al., 2010), we believe that SHP2 inhibition either by itself or incorporated into maintenance therapy for high-risk NB warrants further investigation. This evidence concerns the gene NF1 and neuroblastoma.